Orthopedics

Clinical trials for Orthopedics specialty

  • Description:
    OA is a progressive degenerative disease with a variety of treatment options suggesting that reliable, safe, and effective treatment has yet to be discovered. In search of treatment options, autologous (dog’s own) concentrated platelets appear to show promise as a safe alternative, free of the risks associated with some non-steroidal antiinflammatory agents. The purpose of this study is to establish more data on the emerging C-PET treatment for OA.
    Inclusion criteria:
    Dogs must have a medical history or physical findings of bilateral elbow osteoarthritis.
    Must weigh at least 25 lbs.
    Must be between 18 months and 10 years of age.
    Exclusion criteria:
    Surgery on joint within one year
    systemic steroid administration,
    joint injection with in 4 months
    Adequan injection within one month
    Client benefits:
    The study will cover cost of blood work, radiographs, and C-PET treatment for qualified animals.
    Contact information:
    Diane Welsh
    Clinical Trials Technician
    clinicaltrials@tufts.edu
  • Description:

    Canine borreliosis has been associated with renal failure and death (“Lyme nephritis’) although causation remains speculative. The Ixodes tick in Northeastern U.S. transmits Borrelia burgdorferi, Anaplasma phagocytophilum, and Babesia microti. Babesia microti-like organisms have been associated with anemia, renal failure, and death in dogs in Spain. Babesia microti is known to infect humans and foxes in the Northeastern United States.  We intend to investigate the incidence of babesial infection in dogs with signs suggestive of Lyme nephritis.  We hypothesize that renal failure and death attributed to borrelial infection in dogs (“Lyme nephritis’) is due to infection or co-infection with a Babesia microti-like organism.

    As a control group, we will be obtaining blood samples from dogs presenting to Tufts Foster Hospital for Small Animals for surgical repair of cruciate ligament disease for the presence of Babesia microti-like DNA.

    Inclusion Criteria:                                           

    Control dogs: Healthy dogs presenting for surgical repair of cruciate ligament disease.

    Client Benefits:

    The study will cover the costs of blood testing for Babesia microti-like infection, heartworm disease and exposure to the infectious organisms Ehrlichia canis, Anaplasma phagocytophilum and Borrelia burgdorferi. Your pet’s participation will also allow us to gain information which will help in the diagnosis and management of other patients.

    Contact Information:

    For questions regarding the clinical trial please email the clinical trials technician, Diane Welsh at:  clinicaltrials@tufts.edu

  • Description:

    Standard MRI protocols in small animals use contrast material (gadolinium) via intravenous administration to fully assess a disease process. The dose of the contrast material is generally based on body weight; however, in horses this makes the use of contrast cost prohibitive.

    This study will add information about equine MRI and will determine if regional limb perfusion is a feasible way to deliver contrast medium and allow for better characterization of common injuries in equine athletes. The goal is to determine if this method of contrast material administration will allow increased sensitivity of lesion detection while keeping the overall price of contrast administration reasonable

    Inclusion Criteria:

    • Horses: any sex, age, weight
    • Any horse undergoing MRI as part of its lameness work up for lameness localized to the foot/distal limb.

     

    Client Benefits:

    The study will cover all of the costs associated with the regional limb perfusion as well as the additional anesthesia time and additional MRI sequences. Your horse’s participation will also allow us to gain information about any current injury and will help in the diagnosis of other horses with injuries in the hoof capsule. You understand that your animal’s participation in this study may not alleviate or cure his/her ailment.

    Contact Information:

    For questions regarding the clinical trial please email the clinical trials technician, Diane Welsh at: clinicaltrials@tufts.edu